In the latest session, LifeStance Health Group Inc (NASDAQ: LFST) closed at $6.39 up 2.57% from its previous closing price of $6.23. In other words, the price has increased by $+0.16 from its previous closing price. On the day, 727451 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a deeper understanding of LifeStance Health Group Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.10. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on January 03, 2024, initiated with a Underweight rating and assigned the stock a target price of $7.
On May 15, 2023, TD Cowen Downgraded its rating to Market Perform which previously was Outperform and also upped its target price recommendation from $8 to $9.
Morgan Stanley Upgraded its Equal-Weight to Overweight on January 06, 2023, while the target price for the stock was maintained at $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 01 when Mullins Kevin Michael sold 113,334 shares for $6.54 per share. The transaction valued at 741,204 led to the insider holds 4,690,616 shares of the business.
Mullins Kevin Michael sold 32,056 shares of LFST for $196,183 on Nov 07. The Chief Development Officer now owns 4,803,950 shares after completing the transaction at $6.12 per share. On Nov 06, another insider, Mullins Kevin Michael, who serves as the Chief Development Officer of the company, sold 300 shares for $6.12 each. As a result, the insider received 1,836 and left with 4,836,006 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LFST now has a Market Capitalization of 2.42B and an Enterprise Value of 2.86B. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.41 while its Price-to-Book (P/B) ratio in mrq is 1.66. Its current Enterprise Value per Revenue stands at 2.85 whereas that against EBITDA is -23.08.
Stock Price History:
Over the past 52 weeks, LFST has reached a high of $9.59, while it has fallen to a 52-week low of $4.63. The 50-Day Moving Average of the stock is 6.90, while the 200-Day Moving Average is calculated to be 7.41.
Shares Statistics:
For the past three months, LFST has traded an average of 1.18M shares per day and 971.31k over the past ten days. A total of 375.96M shares are outstanding, with a floating share count of 85.76M. Insiders hold about 77.35% of the company’s shares, while institutions hold 23.47% stake in the company. Shares short for LFST as of Jan 31, 2024 were 25.9M with a Short Ratio of 22.01, compared to 19.7M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 6.84% and a Short% of Float of 34.11%.
Earnings Estimates
There are 7 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.09 for the current quarter, with a high estimate of -$0.07 and a low estimate of -$0.14, while EPS last year was -$0.13. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.02 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.45 and -$0.55 for the fiscal current year, implying an average EPS of -$0.48. EPS for the following year is -$0.27, with 7 analysts recommending between -$0.06 and -$0.41.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $263M this quarter.It ranges from a high estimate of $272.41M to a low estimate of $260M. As of the current estimate, LifeStance Health Group Inc’s year-ago sales were $229.4M, an estimated increase of 14.60% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $299.11M, an increase of 18.40% over than the figure of $14.60% in the same quarter last year. There is a high estimate of $300.51M for the next quarter, whereas the lowest estimate is $297.53M.
A total of 8 analysts have provided revenue estimates for LFST’s current fiscal year. The highest revenue estimate was $1.05B, while the lowest revenue estimate was $1.03B, resulting in an average revenue estimate of $1.04B. In the same quarter a year ago, actual revenue was $859.54M, up 20.70% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $1.2B in the next fiscal year. The high estimate is $1.22B and the low estimate is $1.19B. The average revenue growth estimate for next year is up 15.80% from the average revenue estimate for this year.
